Drug research efficiency Tamsin Fortе in the treatment of men with symptomatic benign prostatic hyperplasia

##plugins.themes.bootstrap3.article.sidebar##

PDF (Русский)
Published: Nov 30, 2016
DOI: https://doi.org/10.30841/2307-5090.4(59).2016.104178
Keywords:
benign prostatic hyperplasia, drug therapy, Tamsin Forte, tamsulozin,

##plugins.themes.bootstrap3.article.main##

І. І. Горпинченко
ГУ «Институт урологии» НАМН Украины, Ukraine
Ю. М. Гурженко
ГУ «Институт урологии» НАМН Украины, Ukraine
В. В. Спиридоненко
ГУ «Институт урологии» НАМН Украины, Ukraine
С. А. Костюченко
Городская клиническая больница No 1, г. Винница, Ukraine
В. М. Красовський
ГУ «Институт урологии» НАМН Украины, Ukraine

Abstract

The paper evaluated the effectiveness of treatment with Tamsin Forte in 55 patients with benign prostatic hyperplasia stage II. The effec tiveness of drug treatment was 92,8%.

##plugins.themes.bootstrap3.article.details##

How to Cite
Горпинченко, І. І., Гурженко, Ю. М., Спиридоненко, В. В., Костюченко, С. А., & Красовський, В. М. (2016). Drug research efficiency Tamsin Fortе in the treatment of men with symptomatic benign prostatic hyperplasia. Health of Man, (4(59), 23–25. https://doi.org/10.30841/2307-5090.4(59).2016.104178
Issue
No. 4(59) (2016)
Section
For practicing physicians
Copyright (c) 2020 І. І. Горпинченко, Ю. М. Гурженко, В. В. Спиридоненко, С. А. Костюченко, В. М. Красовський

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

І. І. Горпинченко, ГУ «Институт урологии» НАМН Украины

I.I. Gorpynchenko

Ю. М. Гурженко, ГУ «Институт урологии» НАМН Украины

Y.N. Gurzhenko

В. В. Спиридоненко, ГУ «Институт урологии» НАМН Украины

V.V. Spiridonenko

С. А. Костюченко, Городская клиническая больница No 1, г. Винница

S.A. Kostyuchenko

В. М. Красовський, ГУ «Институт урологии» НАМН Украины

V.M. Krasovskiy

References

Wilde MI and McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia / Drugs 1996; 52: 883 898.

Wolzt M, Fabrizii V, Dorner GT, Zanaschka G, Leufkens P, Krauwinkel WJ, and Eichler HG. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open label single dose and multiple dose study / Eur J Clin Pharmacol 1998; 54: 367 373.

Dunn CJ, Matheson A, and Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms / Drugs Aging 2002; 19: 135 161.

Andersson KE. Alpha adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha adrenoceptor antagonists/ World J Urol 2002; 19: 390 96.

Miyazawa Y, Forrest A, Schentag JJ, Kamimura H, Swarz H, and Ito Y. Effect of concomitant administration of cimetidine hydrochloride on the pharmacokinetic and safety profile of Tamsulosin hydrochloride 0.4 mg in healthy subjects / Current Therapeutic Research 2002; 63: 15 26.

Maruenda J, Bhatnagar V, and Lowenthal DT. Hypertension in the elderly with coexisting benign prostatic hyperplasia / Urology. 1999; 53: 7 12.

Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect / Clin Ther 1997; 19: 730 742.

Мiyazawa Y, Blum RA, Schentag JJ, Kamimura H, Matsushima H, Swarz H, and Ito Y. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function/ Current Therapeutic Research 2001; 62: 603 621.